FLOT is a four-drug chemotherapy regimen used primarily to treat locally advanced stomach cancer and esophageal cancer. The name is an acronym for its components: fluorouracil (5-FU), leucovorin, oxaliplatin, and taxotere (docetaxel). It’s given before and after surgery to shrink tumors and kill remaining cancer cells, and it has become the standard of care for these cancers in many treatment centers worldwide.
The Four Drugs and What They Do
Each drug in the FLOT regimen attacks cancer cells through a different mechanism, which is part of why the combination works well together.
Fluorouracil (5-FU) is an anti-metabolite, meaning it mimics a building block that cells need to copy their DNA. When cancer cells absorb it, they can’t replicate properly and die. Leucovorin isn’t a cancer-fighting drug on its own. It’s a form of folic acid that makes 5-FU more effective by stabilizing how 5-FU binds to its target inside cells, keeping the drug active longer. Oxaliplatin is a platinum-based drug that works by wedging itself into the DNA strand, preventing cancer cells from reading their genetic instructions and dividing. Docetaxel (the “T” in FLOT, from the brand name Taxotere) disrupts the internal scaffolding that cells need to pull apart during division, essentially freezing cancer cells mid-split.
By combining three distinct ways of killing cancer cells, FLOT makes it harder for tumors to develop resistance to any single drug.
Which Cancers FLOT Treats
FLOT is primarily used for locally advanced gastric (stomach) cancer and gastroesophageal junction cancer, which occurs where the esophagus meets the stomach. “Locally advanced” means the tumor has grown through the stomach or esophageal wall and may have reached nearby lymph nodes, but hasn’t spread to distant organs.
More recently, FLOT has been established as a preferred treatment for locally advanced esophageal cancer as well. A major trial compared FLOT to a combined chemotherapy-and-radiation approach, and based on those results, the National Cancer Institute reported that FLOT should now be considered the standard of care for most people with locally advanced esophageal cancer. The regimen is typically used for adenocarcinomas, the most common type of cancer in these locations.
How FLOT Is Scheduled
The standard FLOT protocol involves eight total cycles, each given every two weeks. In the traditional approach, you receive four cycles before surgery and four cycles after surgery. This “perioperative” strategy (meaning around the time of surgery) aims to shrink the tumor before the operation and then eliminate any microscopic cancer cells that might remain afterward.
Some treatment centers now give all eight cycles before surgery, with no chemotherapy afterward. This “total neoadjuvant” approach is being studied to see whether completing all treatment before surgery leads to better outcomes, partly because many patients struggle to tolerate chemotherapy during surgical recovery.
What Treatment Day Looks Like
FLOT is administered intravenously, and you’ll need a central venous access device, typically a port implanted under the skin of your chest. On treatment day, docetaxel, oxaliplatin, and leucovorin are given through IV infusions at the clinic. The fluorouracil portion is different: it runs continuously over 24 hours through a small portable pump you take home. This means each treatment visit is followed by roughly a day connected to the pump before you return to have it disconnected.
With cycles repeating every 14 days, the preoperative phase takes about two months. After surgery and recovery, the postoperative four cycles add another two months of treatment.
How Effective FLOT Is
FLOT represented a significant improvement over older chemotherapy combinations for stomach and esophageal cancers. The landmark FLOT4 trial compared it to the previous standard regimen (a combination called ECF/ECX) and found that patients on FLOT lived substantially longer. Median overall survival with FLOT was 50 months, compared to 35 months with the older regimen. Real-world data from treatment centers has confirmed similar results, with one analysis finding median survival of nearly 58 months in FLOT-treated patients versus 29 months with older fluorouracil-and-platinum combinations.
These results are what made FLOT the new standard of care, replacing regimens that had been used for years.
Common Side Effects
Nausea and vomiting are the most frequently reported side effects, though anti-nausea medications given alongside treatment help manage them for most people. Diarrhea occurs more often with FLOT than with older regimens.
Peripheral neuropathy, a tingling or numbness in the hands and feet caused primarily by oxaliplatin, affects roughly one in five patients at a mild level. This can sometimes persist after treatment ends, though severe cases are uncommon. Sensitivity to cold is a related effect: cold drinks or cold air on the skin can trigger sharp tingling sensations, particularly in the days after each infusion.
Low white blood cell counts (neutropenia) can occur but appear to be less common with FLOT than with older regimens. In one comparative study, no moderate or severe neutropenia cases were observed among FLOT patients, while the older protocol produced a small number of more serious cases. That said, your medical team will monitor blood counts regularly throughout treatment because low counts increase infection risk.
Fatigue is a near-universal experience with multi-drug chemotherapy regimens, and it tends to build over successive cycles. Hair thinning or loss can happen due to the docetaxel component. Mouth sores are another possible effect of the fluorouracil infusion.
Who Can Receive FLOT
FLOT is an intensive regimen, and not everyone is a candidate. You generally need to be in good overall physical condition. Clinical trials typically require an ECOG performance status of 0 or 1, which means you’re either fully active or restricted in strenuous activity but still able to carry out light work and care for yourself. People with serious heart, kidney, or liver problems, or those with another active cancer, are usually not eligible.
Age alone isn’t a strict cutoff, but because FLOT is a four-drug regimen, older patients or those with multiple health conditions may be offered a modified version or an alternative protocol. The decision depends on a careful assessment of whether the expected benefit outweighs the physical toll of treatment.